Duodenal gastrointestinal stromal tumors (DGISTs) represent a rare subset of mesenchymal neoplasms of the gastrointestinal tract, accounting for approximately 3–5% of all gastrointestinal stromal ...
Association of the genetic variants in the nucleotide excision repair genes XPA and XPC with cisplatin-induced hearing loss in patients with osteosarcoma. Relationship of CUL4A gene underexpression ...
GISTs originate from interstitial cells of Cajal and are staged by size, location, mitotic rate, and genetic mutations, influencing treatment strategies. Diagnosis involves imaging, endoscopy, biopsy, ...
A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...
These study authors hope their findings will inform future research on gastrointestinal stromal tumors (GIST) and close care gaps for minority patient populations. Unfavorable trends in the diagnosis ...
If you have advanced gastrointestinal stromal tumor (GIST), you may not know anyone else with the disease. This may leave you with a lot of questions about what life will be like with this rare cancer ...
HT-KIT demonstrates significant tumor downregulation and over 80% reduction in KIT expression in preclinical models of GIST and systemic mastocytosis. The therapy targets KIT gene expression at the ...
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies PTEN ...
A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...
GIST stands for gastrointestinal stromal tumor. When tumors spread from the gastrointestinal (GI) tract to distant tissues or organs, it is called a metastatic GIST. Newer therapies, such as imatinib ...
Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointestinal Stromal Tumors. Bezuclastinib is a promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback